Treatments against rare dermatological diseases (Ref. UC3M_172)

The developed invention relates to a compound with potential for treating different dermatological diseases with varying origins and symptomatology comprised under the term genodermatosis. These rare diseases, which all have a limited prevalence and rather ineffective treatments at present, include epidermolysis bullosa (EB). The only treatment today is losartan, declared an orphan drug in February 2019, which causes a number of side effects in patients.                                         

INNOVATIVE ASPECTS:

• Provide several treatments for genodermatosis.

• Provide alternative treatments for a type of genodermatosis, that is, epidermolysis bullosa (EB).

• Higher expectation of success and fewer side effects than the only compound described to date for the treatment of EB (losartan).

 COMPETITIVE ADVANTAGES:

• Treatment of rare dermatological diseases for which there is no effective treatment.

• Compounds with marketing authorisations that have already been tested in humans for the treatment of other rare diseases.

STAGE OF DEVELOPMENT: DEVELOPMENT PHASE – LABORATORY.

INTELLECTUAL PROPERTY RIGHTS: Patent applied.